Glatiramer acetate

Cat. No.: HY-109520 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.

For research use only. We do not sell to patients.

Glatiramer acetate Chemical Structure

CAS No. : 147245-92-9

Size	Price	Stock	Quantity
5 mg	USD 80	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 130	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 250	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 400	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 650	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression^[1]^[2]^[3].
In Vitro	Glatiramer acetate (25-100 mg/kg; S.c; 5 days) increase BDNF levels^[3]. In huntington’s disease (HD) mouse model, the N171-82Q transgenic mouse line, which exhibits a more rapidly progressing disease course. Glatiramer acetate (1 mg/mouse; s.c.; 5×week) beginning at 8 weeks of age and continuing until 20 weeks of age, which is near the age of death due to the disease. Glatiramer acetate elicited improves performance on several motor function measures. Glatiramer acetate significantly improves the performance of N171-82Q transgenic mice at 15 weeks of age in the rotarod test measured over the course of 4 days^[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Glatiramer acetate Related Antibodies
Formula	(C₉H₁₁NO₃.C₆H₁₄N₂O₂.C₅H₉NO₄.C₃H₇NO₂)x.xC₂H₄O₂
CAS No.	147245-92-9
Appearance	Solid
Color	White to off-white
SMILES	OC(CC[C@H](N)C(O)=O)=O.OC([C@@H](N)CC1=CC=C(O)C=C1)=O.OC([C@@H](N)C)=O.NCCCC[C@H](N)C(O)=O.O=C(C)O.[x].[x].[x].[x].[x]
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility	In Vitro: H₂O : 50 mg/mL (Need ultrasonic) Molarity Calculator Dilution Calculator Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Mass = Concentration × Volume × Molecular Weight * Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final) This equation is commonly abbreviated as: C₁V₁ = C₂V₂ Concentration _(start) C1 × Volume _(start) V1 = Concentration _(final) C2 × Volume _(final) V2 In Vivo Dissolution Calculator Please enter the basic information of animal experiments: Dosage mg/kg Animal weight (per animal) g Dosing volume (per animal) μL Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments. Calculation results: Working solution concentration: mg/mL This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details. The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE). Tel: 609-228-6898 E-mail: [email protected] Technical Support: [email protected]
Purity & Documentation	Purity: ≥98.0% Select Batch: Data Sheet (273 KB) SDS (252 KB) COA (251 KB) HNMR (216 KB) Handling Instructions (2659 KB)
References	[1]. McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29(5):425-432. [Content Brief] [2]. Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2(Suppl 2):14593-14598. [Content Brief] [3]. Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110. [Content Brief] [4]. Aharoni R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [published correction appears in Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12288]. Proc Natl Acad Sci U S A [Content Brief]